Anti-Human SLC1A5 Recombinant Antibody (cKM4008) (CAT#: TAB-1009CLV)

Figure 1 The reactivity of an anti-ASCT2 human chimeric antibody to human ASCT2-myc/His gene-introduced CHO cells (ASCT2/CHO) and human multiple myeloma cell line OPM-2 by means of fluorescent cell staining (flow cytometer).

The abscissa represents an antibody concentration ( μg/ml), and the ordinate represents a mean fluorescence intensity. The mean fluorescence intensity is indicated by ◯ and solid line for cKM4008, by ∆ and solid line for cKM4012, and by ■ and solid line for cKM4018.

Figure 2 The ADCC activity of an anti-ASCT2 human chimeric antibody on the human multiple myeloma cell line KMS-11.

The abscissa represents an antibody concentration ( ng/ml), and the ordinate represents an ADCC activity. The ADCC activity is indicated by ◯ and solid line for cKM4008, by ∆ and solid line for cKM4012, and by ■ and solid line for cKM4018.

Figure 3 The CDC activity of an anti-ASCT2 human chimeric antibody on human ASCT2-myc/His gene-introduced CHO cells (ASCT2/CHO) and human colorectal cancer cell line Colo205.

The abscissa represents an antibody concentration ( μg/ml), and the ordinate represents a CDC activity. The CDC activity is indicated by ◯ and solid line for cKM4008, by ∆ and solid line for cKM4012, and by ■ and solid line for cKM4018.

Figure 4 The inhibitory activity of anti-ASCT2 human chimeric antibodies on glutamine-dependent proliferation of the human colorectal cancer cell line WiDr.

The abscissa represents a final concentration ( μg/ml) of individual antibodies, and the ordinate represents a relative value (%) obtained by taking proliferation of non-antibody treated cells to be 100%. The relative proliferation rate is indicated by ◯ and solid line for cKM4008, by ∆ and solid line for KM4012, by ■ and solid line for KM4018, by + and solid line for KM511 and by dotted line for AST mixture.

Figure 1 Anti-Human SLC1A5 Recombinant Antibody (TAB-1009CLV) in SDS-PAGE

SDS-PAGE analysis of TAB-1009CLV in non-reduced (Lane 2) and β-mercaptoethanol-reduced (Lane 1) conditions.

Figure 2 Anti-Human SLC1A5 Recombinant Antibody (TAB-1009CLV) in HPLC

The purity of TAB-1009CLV was greater than 95% as determined by SEC-HPLC.

Figure 3 Anti-Human SLC1A5 Recombinant Antibody (TAB-1009CLV) in FC

Flow cytometry analysis of HT29 cells with purified antibody TAB-1009CLV (Blue). Cells were then incubated with TAB-1009CLV (5 μl/5x10⁵ cells) for 60 min at 4°C. The secondary antibody was FITC anti-human IgG antibody.